Okay, so we must assume the court had enough evidence of wrongdoing for a ruling to grant the travel restriction and refer to the matter before a judge in August.
This should not prevent DUB from communicating updates to shareholders about where the $26M was supposed to be held, who it was trusted to, where it is now, and what chance of recovery.
More concerning, for now, is the lack of a half-yearly audited report. If the issue was only the missing $26M, wouldn’t they only need to restate the ‘cash on hand’ or ‘call deposits’ balance, to reflect the truth, and then move forward? I am guessing they may be trading insolvent and must complete the CR before they are unsuspended.
Even with the quick $1.5M AW bridging loan to keep lights on, and the recovered $3.4M, by quick calculation, $1.5M + $3.4M = call it $5M is cash on hand, then Customer Receipts for current QTR call that $9M, minus Expenses for QTR being $13M, equals $1M balance, as of about now.
Can someone explain to me how revenue for Q2 in FY24 was $10.7M. We have actual Customer Receipts for Q2 in FY24 being $8.8M. But then they normalised this for reporting to $9.7M by counting late payments expected in December but expected in January. Okay a little fiddling here, but how does it reach $10.7M?
Does anyone think they are still on track to achieve the full-year revenue guidance of $45M? The pre-audited half-yearly receipts were $18M, so I’m not confident that $45M is achievable.
If we ever get there the 4C report in Q3 FY24 will be compulsory reading.
- Forums
- ASX - By Stock
- Dubber.Dubber.Do.
DUB
dubber corporation limited
Add to My Watchlist
5.56%
!
1.7¢

Okay, so we must assume the court had enough evidence of...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
1.7¢ |
Change
-0.001(5.56%) |
Mkt cap ! $44.59M |
Open | High | Low | Value | Volume |
1.8¢ | 1.8¢ | 1.7¢ | $54.89K | 3.121M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
15 | 6119479 | 1.7¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
1.8¢ | 4342422 | 6 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
15 | 6119479 | 0.017 |
17 | 5494713 | 0.016 |
20 | 9716350 | 0.015 |
8 | 4014422 | 0.014 |
2 | 54411 | 0.013 |
Price($) | Vol. | No. |
---|---|---|
0.018 | 4342422 | 6 |
0.019 | 1421921 | 7 |
0.020 | 3191226 | 3 |
0.021 | 757193 | 6 |
0.022 | 604812 | 3 |
Last trade - 13.06pm 04/07/2025 (20 minute delay) ? |
Featured News
DUB (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Dr Michael Thurn, CEO & MD
Dr Michael Thurn
CEO & MD
SPONSORED BY The Market Online